Autonomix Medical Inc. (AMIX): Market Cap to Revenue
The P/S trajectory of Autonomix Medical, Inc. (AMIX) demonstrates volatility despite the uniqueness of its pain management catheters and high margins. The current level stands at , driven by a lack of current sales and regulatory challenges. Future profit growth will be fueled by the delivery of hypertension therapy devices to cardiology centers, replacing traditional pharmacological support.
Analytical breakdowns for Autonomix Medical, Inc. (AMIX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Autonomix Medical, Inc.|AMIX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio autonomix.com|AMIX - Company Aggregate Debts|Debts to Book Capitalization Autonomix|AMIX - Company Long-Term Debt|Company Short-Term Debt Autonomix Medical|Intermediate Coverage Ratio autonomix.com
- earnings and multiples data:
AMIX - Net Profit|Expected Net Profit Autonomix Medical, Inc.|AMIX - Price to Earnings Ratio|Forward Price to Earnings Multiple autonomix.com|AMIX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Autonomix|AMIX - Operating profit EBITDA|Net earnings per share for the last four quarters Autonomix Medical|AMIX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months autonomix.com|AMIX - Earnings per share growth in current year|Expected earnings per share growth for next year Autonomix Medical, Inc.
- issuer revenue and sales details:
General company analysis:AMIX Autonomix Medical Inc.
For Autonomix Medical, Inc. (AMIX), whose prospects depend on clinical trials and liquidity, P/S volatility reflects the market's valuation of neurosensing potential relative to current sales. This ratio compares market capitalization to revenue, allowing investors to determine the extent of the premium paid for future growth or the risk of asset undervaluation amid high regulatory pressure and limited cash flow.
Competitors of Autonomix Medical, Inc.
BSX (bostonscientific.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Edwards Lifesciences Corporation EW|RMD - Market Cap to Revenue|OmniPod - P/S Multiple|Price to Sales Zimmer Biomet Holdings|COO: P/S Multiple|Market Cap to Revenue Ratio ALGN|GMED (Globus Medical) - P/S Multiple|TransMedics Group Inc (TMDX) - Price-to-Revenue Coefficient|P/S Multiple ATEC|Market Cap to Revenue Artivion Corp AORT|P/S Multiple ENOV (Enovis Corporation)|P/S Multiple integralife.com IART|ESTA - Price-to-Revenue Ratio|BBNX: Price-to-Revenue Ratio|IRMD (Iradimed) - Market Cap to Revenue|Embecta Health - Market Capitalization-to-Revenue Ratio|TNDM (Tandem Diabetes Care) - P/S Multiple|Price to Sales axogeninc.com AXGN|Price-to-Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Price-to-Revenue Multiple|Bioventus Corp - Market Cap to Revenue|P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - P/S Multiple|Price-to-Revenue Coefficient blade.com SRTA|Carlsmed (CARL) - Price-to-Revenue Ratio|Price-to-Sales Ratio RXST (RxSight Inc)|Price-to-Revenue Ratio ClearPoint Neuro Inc.|Market Cap to Revenue Stereotaxis Corporation (STXS)|P/S Multiple STIM|SGHT - Price to Sales|Price-to-Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Revenue Ratio|NSPR: Market Cap to Revenue|Jin Medical International - Market Cap to Sales Volume|VANI: P/S Multiple|Xtant Medical (XTNT) - P/S Multiple|Market Cap to Revenue NMTC|P/S Multiple Modular Med|Market Cap to Revenue MYO (Myomo, Inc)|Market Cap to Sales Volume COCH|Price-to-Revenue Ratio Vivos Therapeutics VVOS|envveno.com (NVNO) - Price to Sales|SINT - Price-to-Revenue Ratio|TNON (Tenon Medical Inc.) - Market Cap to Revenue Ratio|ReWalk Robotics Ltd (LFWD) - Price-to-Revenue Ratio|Price to Sales INVO Fertility Corp (IVF)|Price-to-Revenue Ratio Bone Biologics|Market Cap to Revenue axonics.com (AXNX)|P/S Multiple BIOL|Price-to-Revenue Coefficient dynatronics.com|Paragon 28 - Market Cap to Revenue|INVO: Market Cap to Revenue Ratio
